https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4
Skip to content 
The Roche Holding AG headquarters on April 11, 2025, in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to … Read more
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk on Wednesday flagged promising late-stage … Read more
Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medications: pills. Both companies expect to launch oral obesity drugs in the U.S. next year, once regulators approve them. Daily pills could introduce more people to GLP-1s, the class of medicine that’s best known for weekly shots. But … Read more
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial, … Read more
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in … Read more
An experimental pill made by Eli Lilly led to average weight loss of more than 12 percent of body weight in individuals with obesity, according to initial trial results announced by the drugmaker on Thursday. The pill is meant to be taken daily and would be an alternative to the company’s popular anti-obesity drug Zepbound, … Read more
The health of U.S. children has deteriorated over the past 17 years, with kids today more likely to have obesity, chronic diseases and mental health problems like depression, a new study says. Much of what researchers found was already known, but the study paints a comprehensive picture by examining various aspects of children’s physical and mental health at the same … Read more
Lilly expects orforglipron obesity results in third quarter
Eli Lilly’s daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic, according to new data from a Phase 3 trial. The results were announced today at the annual meeting of the American Diabetes Association and published in … Read more
While injected GLP-1 drugs are incredibly effective at spurring weight loss, they also come with some downsides. There can be gastrointestinal side effects and loss of muscle mass. The drugs are also expensive, at $1,000 a month or more in the US before insurance. Drug companies are interested in developing anti-obesity pills because of their … Read more
https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4